원발성 담즙성 담관염 치료 시장 : 치료 유형별, 유통 채널별, 지역별

The global primary biliary cholangitis treatment market is anticipated to witness substantial growth during the forecast period (2023-2030). It is projected to expand from US$ 650 million in 2023 to reach US$ 1,174.1 million by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%.

Figure 1. Global Primary Biliary Cholangitis Treatment Market Share (%), By Region, 2023

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that affects the small bile ducts in the liver. As the disease progresses, it causes scarring and injury to these bile ducts, known as bile ductules, which stops bile from flowing freely within the liver and damaging it over time. Some key symptoms of PBC include fatigue, itching, and jaundice. If left untreated, PBC can eventually result in cirrhosis or liver failure. The primary biliary cholangitis treatment market consists of drugs that target various pathways involved in the pathogenesis and progression of the disease. Ursodeoxycholic acid (UDCA) remains the first-line treatment but many patients do not adequately respond or are intolerant to it. Second-line treatments such as obeticholic acid and fibric acid derivatives are emerging to address the unmet needs.

Market Dynamics:

The primary biliary cholangitis treatment market is primarily driven by the rising prevalence of PBC globally. According to various estimates, the global prevalence of PBC ranges between 40 and 400 cases per million. The market is also propelled by the launch of novel second-line treatment options with higher efficacy and better tolerability profiles than conventional therapies. However, the market growth can be restrained by the high costs of newer drugs and lack of awareness about PBC in developing regions. Emergence of pipeline drugs with novel mechanisms of action represents an opportunity for players in this market. Regulatory approval of efficient and safe therapies can help address the needs of refractory patients.

Key Features of the Study:

• This report provides an in-depth analysis of the global primary biliary cholangitis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global primary biliary cholangitis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc., Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, and Kaken Pharmaceutical Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global primary biliary cholangitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cholangitis treatment market

Detailed Segmentation:

• By Treatment Type:
  • Ursodeoxycholic Acid (UDCA)
  • Obeticholic Acid (Ocaliva)
  • Others (Fibrates (Tricor), etc.)
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Intercept Pharmaceuticals, Inc.
  • Highlight Therapeutics, S.L.
  • GSK plc.
  • Bristol-Myers Squibb and Company
  • Enanta Pharmaceuticals
  • NW Biotherapeutics
  • Merck & Co Inc.
  • Ipsen Pharma
  • Johnson & Johnson
  • GENFIT
  • Ironwood Pharmaceuticals, Inc.
  • Novartis AG
  • COUR Pharmaceuticals
  • Kaken Pharmaceutical Co., Ltd.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Primary Billiary Cholangitis Treatment, By Treatment Type
  • Market Primary Billiary Cholangitis Treatment, By Distribution Channel
  • Market Primary Billiary Cholangitis Treatment, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing Prevalence of Primary Biliary Cholangitis
  • Growing Adoption of Novel Drugs
  • Increasing adoption of Combination Therapy
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Primary Biliary Cholangitis Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• Ursodeoxycholic Acid (UDCA)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Obeticholic Acid (Ocaliva)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Others (Fibrates (Tricor), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Primary Biliary Cholangitis Treatment Market, By Region, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
• India
• China
• Japan
• Australia
• ASEAN
• South Korea
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Mn)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Intercept Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Highlight Therapeutics, S.L.
• GSK plc.
• Bristol-Myers Squibb and Company
• Enanta Pharmaceuticals
• NW Biotherapeutics
• Merck & Co Inc.
• Ipsen Pharma
• Johnson & Johnson
• GENFIT
• Ironwood Pharmaceuticals, Inc.
• Novartis AG
• COUR Pharmaceuticals
• Kaken Pharmaceutical Co., Ltd.
• Analyst Views

9. Section

• Research Methodology
• About us